以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 从资金流向上来看，当日精准医疗板块主力资金净流出1.01亿元，游资资金净流出1.64亿元，散户资金 净流入2.65亿元。精准医疗板块个股资金流向见下表： 证券之星消息，12月17日精准医疗板块较上一交易日上涨1.16%，迪安诊断领涨。当日上证指数报收于 3870.28，上涨1.19%。深证成指报收于13224.51，上涨2.4%。精准医疗板块个股涨跌见下表： ...

Core Insights - The precision medicine sector experienced a slight increase of 0.53% on December 12, with BGI Genomics leading the gains [1] - The Shanghai Composite Index closed at 3889.35, up 0.41%, while the Shenzhen Component Index closed at 13258.33, up 0.84% [1] Stock Performance - BGI Genomics (688114) saw a closing price of 64.50, with a significant increase of 7.68% and a trading volume of 86,400 shares, resulting in a transaction value of 540 million yuan [1] - Other notable performers included: - BGI (300676) with a closing price of 45.71, up 3.86% [1] - Wondfo Biotech (300685) at 21.55, up 1.41% [1] - Berry Genomics (000710) at 11.18, up 0.72% [1] - WuXi AppTec (603259) at 94.05, up 0.70% [1] Capital Flow - The precision medicine sector saw a net outflow of 1.022 billion yuan from institutional investors, while retail investors contributed a net inflow of 586 million yuan [2] - The capital flow for specific stocks included: - BGI Genomics (688114) had a net inflow of 22.93 million yuan from institutional investors [3] - Anke Bio (300009) experienced a net inflow of 3.38 million yuan from institutional investors [3] - However, ST Xiangxue (300147) faced a net outflow of 2.93 million yuan from institutional investors [3]

Core Viewpoint - The strategic collaboration between Mirxes and Jingtai Technology aims to integrate their strengths in early cancer detection and drug development, creating a comprehensive "diagnosis and treatment integration" solution for high-incidence cancers in Asia [1] Collaboration Model - The partnership focuses on building a closed-loop ecosystem of "detection + research" [2] - Mirxes will act as a "frontline detection and risk assessment expert" utilizing its leading position in blood-based miRNA cancer screening [3] - Jingtai Technology will serve as an "intelligent drug discovery engine" leveraging quantum physics, AI, and robotic experimentation [3] - Both companies plan to create a disease database focused on the Asian population to drive the discovery of new diagnostic markers and therapeutic targets [3] Strategic Intent - This collaboration signifies Mirxes' strategic shift from solely "early diagnosis" to a broader "diagnosis and treatment integration" approach [4] - By closely aligning with upstream drug development platforms, the company aims to participate in higher-value treatment segments, enhancing its competitive barriers and customer loyalty [5] Fundamental Support - Mirxes' strategic advancement is backed by improving fundamentals [6] - Recent business expansions include inclusion in the Hang Seng Composite Index, endorsement from Malaysia's sovereign fund, and obtaining key market access qualifications [7] - The company reported a revenue of $10.5 million in the first half of the year, with core early screening business revenue growing by 50% year-over-year [7] - Gross margin improved significantly from 49% to 67.6%, indicating strong product capability and cost control [7] - Cash reserves reached $108 million, providing financial flexibility for R&D collaboration and market expansion [7] Investment Perspective - Mirxes currently exhibits strong growth in core business and a clear long-term strategy [8] - Short-term certainty is based on the commercial progress of its gastric cancer screening and the effectiveness of its high-margin business model [9] - Long-term potential is enhanced by collaborations with major players like Watson and Jingtai, which open avenues for extending from diagnostic data to treatment [9] Conclusion - The strategic partnership between Mirxes and Jingtai Technology represents a forward-looking move to break through the limitations of the early screening industry and tap into the larger precision medicine market [11] - The company is at a critical juncture of "performance realization" and "model transition," necessitating attention to both existing business growth and the potential value creation from the new ecosystem [12]

来源：猎云网 近日，精准医疗企业吉因加完成3亿元D轮融资，本轮融资由绍兴市越城区科创引智基金、北京昌平产业发展投资基金等联合投资。 据了解，本轮融资将主要用于AI多组学技术研发、biomarker创新管线拓展及全球服务网络深化，进一步强化公司在精准诊断、新药研发等应用场景的全链 条服务能力，助力AI驱动的多组学技术从科研加速迈向临床转化。 吉因加科技（绍兴）股份有限公司成立于2015年4月，深耕精准医疗赛道，前瞻性推动基因大数据与临床实践的深度融合，在行业内率先建立多组学基线数 据库，构建起AI驱动的多组学平台，打造了"biomarker 发现&验证-产品化-商业化"全链条整合模式。在肿瘤MRD监测、NGS一体化精准诊断平台等领域取 得显著突破，业务覆盖肿瘤、感染、器官健康等多个疾病领域。 吉因加总裁杨玲表示，"我们始终聚焦临床需求，致力于将AI多组学创新技术转化为可及、可靠的临床解决方案。借助本轮融资的强大助力，我们将加大AI 多组学研发投入，加速MRD监测、肿瘤早筛等核心产品的转化与落地，同时积极拓展更多疾病诊断与治疗的应用新场景，持续夯实商业化全链条能力，让 AI多组学技术惠及更多患者与药企，为精准医疗 ...

投资界12月1日消息，近日，国内领先的精准医疗企业吉因加科技（绍兴）股份有限公司（以下简称"吉 因加"）宣布完成3亿人民币的D轮融资。本轮融资由绍兴市越城区科创引智基金、北京昌平产业发展投 资基金等联合投资，资金将主要用于AI多组学技术研发、biomarker创新管线拓展及全球服务网络深 化，进一步强化公司在精准诊断、新药研发等应用场景的全链条服务能力，助力AI驱动的多组学技术 从科研加速迈向临床转化。 绍兴市越城区科创引智基金管理人表示："精准医疗是国家重点支持的战略性新兴产业，市场前景广 阔。吉因加在技术研发、临床转化等方面积累深厚，具备强劲的发展势能。此次投资是基于对企业核心 价值与行业发展趋势的坚定看好，未来将持续助力企业深耕赛道、拓展布局。" 北京昌平产业发展投资基金管理人昌发展表示："北京昌平正全力打造全球领先的'生命谷'，AI+精准医 疗是区域重点支持的前沿赛道，也是医疗健康领域新质生产力的重要组成。吉因加作为 AI 精准医疗领 域的领军者，在技术创新与商业化落地方面表现亮眼，其发展方向与昌平产业布局高度契合，通过此次 合作将共同推动精准医疗技术普及，赋能区域医疗健康产业高质量发展。" 吉因加总 ...

Core Insights - The precision medicine sector experienced a 1.92% increase on November 24, with Guomai Technology leading the gains [1] - The Shanghai Composite Index closed at 3836.77, up 0.05%, while the Shenzhen Component Index closed at 12585.08, up 0.37% [1] Stock Performance - Guomai Technology (002093) closed at 12.19, up 10.02% with a trading volume of 446,600 shares and a transaction value of 536 million [1] - Zhongyuan Xiehe (600645) also rose by 10.02% to 28.23, with a trading volume of 169,100 shares and a transaction value of 468 million [1] - Other notable performers include: - Toukeng Life (300642) at 19.51, up 3.34% [1] - Beirui Gene (000710) at 11.97, up 3.28% [1] - Yangjin Medical (300030) at 7.90, up 3.27% [1] Capital Flow - The precision medicine sector saw a net inflow of 526 million from institutional investors, while retail investors experienced a net outflow of 143 million [2] - The main capital inflow and outflow for key stocks include: - WuXi AppTec (603259) with a net inflow of 251 million [3] - Guomai Technology (002093) with a net inflow of 241 million [3] - Zhongyuan Xiehe (600645) with a net inflow of 102 million [3]

Market Overview - The precision medicine sector experienced a decline of 1.61% on November 21, with Berry Genomics leading the drop [1] - The Shanghai Composite Index closed at 3834.89, down 2.45%, while the Shenzhen Component Index closed at 12538.07, down 3.41% [1] Stock Performance - Key stocks in the precision medicine sector showed varied performance, with the following notable changes: - United Imaging Healthcare (688271) increased by 2.15% to a closing price of 133.50 [1] - Berry Genomics (000710) fell by 8.67% to a closing price of 11.59, with a trading volume of 233,200 shares and a turnover of 278 million [2] - WuXi AppTec (603259) decreased by 2.00% to a closing price of 91.80, with a significant trading volume of 346,800 shares and a turnover of 3.197 billion [1] Capital Flow - The precision medicine sector saw a net outflow of 678 million from institutional investors, while retail investors contributed a net inflow of 705 million [2] - The following stocks experienced notable capital flows: - New Open Source (300109) had a net inflow of 22.76 million from institutional investors [3] - ST Xiangxue (300147) faced a significant net outflow of 17.12 million from institutional investors [3]

从西门子的数字科技，到世和基因的精准医疗；从M&J医疗集团的国际视野，到江苏国际数据港的跨 境数据流；从全国罕见的联营律师事务所，到新型金融租赁公司……这些来自不同赛道的声音，奏响了 同一个旋律：看好南京。 "南京的产业生态与我们数字化转型的战略非常契合。"西门子（中国）副总裁胡建钧表示。而在世和基 因副总经理蒋斯明看来，南京雄厚的生物医药产业基础和人才储备，是企业能在此快速成长的"阳光雨 露"。 全国首批联营律师事务所之一的高级合伙人毕哲琳，则从法律实践的角度，带大家感知南京制度创新 的"脉搏"。"这里的开放姿态和法治化营商环境，让我们能真正探索跨境法律服务的新模式。" 会场内，思想的火花不断碰撞；会场外，合作的种子已然播下。江北新区、鼓楼区的专题推介，不再是 简单的招商宣讲，而是精准抛出合作的"橄榄枝"。 这场交流会清晰地传递出一个信号：南京的服务业扩大开放，不是单方面的政策给予，而是一场与全球 企业家的"双向奔赴"。 扬子晚报网11月19日讯（记者 陈哲 实习生 潘伊笑）19日，一场关于"开放"与"合作"的高水平对话在宁 开启。江苏省商务厅副厅长陈晓冬在服务业扩大开放交流会上指出，省商务厅将全力支持南京 ...

Myriad Genetics Conference Call Summary Company Overview - **Company**: Myriad Genetics (NasdaqGS:MYGN) - **Focus Areas**: Precision medicine, hereditary cancer testing, women's health testing, mental health, therapy selection, and minimal residual disease (MRD) [4][6][18] Key Points and Arguments Company Transformation - Myriad Genetics has undergone significant changes over the past year, characterized by positive momentum and a clearer strategy focused on predictable and profitable growth [6][7] - The company aims to grow at or above market rates in prenatal and mental health sectors while prioritizing the cancer care continuum [7][18] - The leadership team has been strengthened with new hires, including a Chief Commercial Officer and a Senior Vice President of Product, to enhance execution and innovation [10][11] Financial Outlook - Myriad targets a high single-digit to low double-digit growth rate over the next three to five years, emphasizing profitability alongside growth [7][14] - The hereditary cancer testing segment is projected to generate approximately $370 million in revenue, accounting for about 45% of total sales, with growth in the low single digits [28] Market Opportunities - The hereditary cancer market is valued at approximately $5 billion, with less than 30% penetration, indicating substantial growth potential [33] - Myriad is expanding its offerings beyond hereditary cancer testing to include therapy selection and MRD, aiming to capture a larger share of the cancer care continuum [18][62] Product Development and Launches - Myriad recently launched an updated MyRisk hereditary cancer panel and plans to introduce several new products over the next 12 months [11] - The company is preparing for the launch of its Precise MRD assay, which aims to differentiate itself through advanced detection capabilities [45][52] Strategic Partnerships - Myriad has formed a partnership with SOPHiA GENETICS and Memorial Sloan Kettering to enhance its liquid biopsy offerings, leveraging their expertise in biomarker discovery and validation [60][61] - The collaboration is expected to ramp up relationships with pharmaceutical partners, facilitating revenue generation ahead of the full commercial launch of MRD [58][60] Internal Metrics and KPIs - Myriad is focused on tracking key performance indicators (KPIs) such as revenue growth, adjusted EBITDA, gross margin, and customer satisfaction metrics to measure success [27][26] - The company is committed to managing resources effectively, ensuring that efforts are concentrated on the cancer care continuum [19][27] Additional Important Insights - Myriad acknowledges the need for a disciplined approach to its portfolio, remaining open to potential changes to optimize its business focus [19][20] - The company is positioning itself to leverage its existing infrastructure and capabilities to accelerate time-to-market for new products [22][23] - Myriad's strategy includes a controlled launch for its MRD assay to ensure proper market adoption and financial management [52][53] This summary encapsulates the key discussions and strategic directions outlined during the Myriad Genetics conference call, highlighting the company's commitment to growth, innovation, and market leadership in the precision medicine space.

Market Overview - The precision medicine sector experienced a slight decline of 0.01% on November 12, with Guomai Technology leading the drop [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] Stock Performance - Zhongyuan Xiehe saw a significant increase of 10.00%, closing at 28.61 with a trading volume of 311,400 shares and a transaction value of 857 million [1] - Yangpu Medical and Beilu Pharmaceutical also reported gains of 4.13% and 2.96%, respectively [1] - Guomai Technology, on the other hand, declined by 3.17%, closing at 11.62 [2] Capital Flow - The precision medicine sector saw a net inflow of 311 million from institutional investors, while retail investors experienced a net outflow of 318 million [2] - Major stocks like Zhongyuan Xiehe and Yaoming Kangde attracted significant institutional investment, with net inflows of 1.941 billion and 76.27 million, respectively [3] Individual Stock Highlights - Zhongyuan Xiehe had a net institutional inflow of 1.941 billion, accounting for 22.65% of its trading volume, while retail investors withdrew 932 million [3] - Yaoming Kangde also saw a net institutional inflow of 76.27 million, with retail investors withdrawing 430 million [3] - Other notable stocks with positive institutional inflows include Beilu Pharmaceutical and Yangpu Medical, with net inflows of 33.03 million and 26.56 million, respectively [3]